For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development, net of grants | 4,390 | 4,209* | 4,519 | 4,759 |
| General and administrative, net of grants | 2,427 | 2,067* | 2,206 | 2,703 |
| Total operating expenses, net | 6,817 | 6,275 | 6,725 | 7,462 |
| Loss from operations | -6,817 | -6,275* | -6,725 | -7,462 |
| Other income, net | 37 | 178* | 195 | 318 |
| Net loss | -6,780 | -6,098 | -6,530 | -7,144 |
| Basic EPS | -0.08 | -0.089 | -0.11 | -0.12 |
| Diluted EPS | -0.08 | -0.089 | -0.11 | -0.12 |
| Basic Average Shares | 81,269,000 | 68,212,000 | 59,711,000 | 59,244,000 |
| Diluted Average Shares | 81,269,000 | 68,212,000 | 59,711,000 | 59,244,000 |
Vivani Medical, Inc. (VANI)
Vivani Medical, Inc. (VANI)